1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6CE687DC37D25C17585257EB60067E682
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-benchmarking-biopharma-quality-capa-processes-quality-resource-management?opendocument
18
19opendocument
2054.81.69.220
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Quality, Compliance and Regulatory » Assuring Quality Programs

Benchmarking BioPharma Quality and CAPA Processes: Quality Resource Management

ID: 5378


Features:

11 Info Graphics

18 Data Graphics

250+ Metrics

3 Narratives


Pages/Slides: 41


Published: 2015


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Benchmarking BioPharma Quality and CAPA Processes: Quality Resource Management"


STUDY OVERVIEW

Biopharmaceutical companies spend millions to ensure their products meet Quality standards at every stage of the product life cycle, from R&D to post-market activity.

Facing tight budgets and escalating regulations, Quality leaders walk a tight rope in balancing quality and safety while managing costs and assessing risk. Across the myriad Quality activities, where are leaders currently spending the most? How do Quality leaders expect spend to change during the coming years across a key set of quality activities? What factors are driving cost of quality?

Research and consulting leader Best Practices, LLC undertook a new study to answer these questions and more. Topics addressed in this study include: how companies define and allocate Quality spend, and factors that impact spending levels. Leaders can use this research to compare their levels of spend across key Quality areas with their peers.

This study presents two segments on some questions: All Participants and Large Companies

KEY TOPICS

  • Quality Spend Levels and Trends
  • Quality Spend Mix
  • Quality Reporting and Ownership
  • Quality Spend Drivers
  • Best Practices for a Robust Quality Function

SAMPLE KEY METRICS
  • Percentage of total quality function budget allocated to these critical quality channels (compliance, nonconforming, etc.)
  • Expected change in allocations to quality budget for these key channels (compliance, nonconforming, etc.)
  • Total spend of quality function in 2014
  • Quality spend inclusions and exclusions for 2014
  • Actual and desired percentage of resources allocated to these cost of quality categories (appraisal, prevention, etc.)
  • Categories used when reporting cost of quality
  • Role (lead, support, none) of these key functions in cost of quality budgeting and ownership
  • Impact of these factors on increasing the cost of quality

SAMPLE KEY FINDING
  • Quality Spend Mix: Benchmarked companies have a critical improvement area for allocating higher percent of their quality budget to prevention and this change may decrease budget allocated to appraisal activities and external failures.
  • Quality Reporting and Ownership: It’s important for companies to align quality ownership with quality budget management. As the functions that have the ownership of quality activities obtain more financial resources and responsibilities, budget allocation to several activities will be more effective.
METHODOLOGY

Best Practices, LLC recruited Quality function and CAPA Process executives at 14 biopharmaceutical organizations to share their data and insights in a customized benchmarking study.

Industries Profiled:
Pharmaceutical; Medical Device; Biotech; Manufacturing; Biopharmaceutical; Health Care


Companies Profiled:
Roche; Biogen; Amgen; Baxalta; UCB Pharma; AstraZeneca; Genzyme; Eisai; GlaxoSmithKline ; United Therapeutics; RIEMSER Pharma; ohm Laboratories; Valeant; Douglas Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.